ClinicalTrials.gg
RecruitingNCT07275697WAITUpdated Aug 10, 2026

Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study

A Phase 4 interventional study of Semaglutide 2.4 mg and Standard medical treatment in Atrial Fibrillation (AF) and Obesity & Overweight, sponsored by Emma Svennberg. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Emma Svennberg · Phase 4, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 135 studies in Atrial Fibrillation with a site in Sweden — 24 open to participants now, 36 under way, 5 of them phase 3. Atrial Fibrillation · Sweden.

Planned enrollment
63rd of 95
200 · median 361
Started
2026
with 2 others
Phase 4
6 of 135
2 open now
Primary completion
2028-12
later than 29 of 35 live
Registered
130th of 135
by date

Among the 135 studies in Atrial Fibrillation with a site in Sweden, this one is the 63rd largest by planned enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 29 of the 35 other live ones, and was the 130th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

24 of the 135 studies in Atrial Fibrillation with a site in Sweden are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Atrial Fibrillation with a site in Sweden, or all of them as a file.
02

Study summary

Atrial fibrillation (AF) is the most common heart rhythm disorder and is associated with symptoms, reduced quality of life, heart failure, stroke, and a high risk of recurrence after catheter ablation. Many patients scheduled for their first ablation are overweight or have obesity, which is one of the strongest predictors of AF recurrence. Weight loss and risk-factor management are known to improve the outcome of ablation, but lifestyle changes are often difficult to achieve in routine care.

Semaglutide (Wegovy®) is a GLP-1 receptor agonist approved in the EU for weight management. It has been shown to produce substantial and sustained weight loss and to improve metabolic and cardiovascular risk factors. Whether treatment with semaglutide before AF ablation can improve long-term rhythm outcomes has never been tested in a randomized clinical trial.

The WAIT-AF study is a randomized, open-label trial with blinded endpoint assessment. The study includes adults with AF who are scheduled for their first catheter ablation and have a BMI ≥30 kg/m², or ≥27 kg/m² with at least one additional cardiovascular risk factor (such as hypertension, diabetes and dyslipidemia). A total of 200 participants will be enrolled.

Participants are randomly assigned in a 1:1 ratio to either standard care or semaglutide (plus lifestyle advice) prior to their scheduled ablation. Semaglutide is administered according to the approved EU label with gradual dose escalation. All participants receive an implantable loop recorder (ILR) before ablation to continuously monitor heart rhythm throughout the study.

The primary objective is to determine whether semaglutide improves arrhythmia-free survival 12 months after AF ablation. Recurrence is defined as AF, atrial flutter, or atrial tachycardia lasting ≥30 seconds on continuous ILR monitoring, excluding the standard 3-month blanking period.

Secondary outcomes include weight loss, changes in blood pressure, AF symptoms, quality of life, AF burden, need for repeat ablation, hospitalizations for cardiovascular causes, and changes in metabolic risk factors. The study also evaluates safety and tolerability of semaglutide in this patient population.

The study aims to determine whether targeted weight management with semaglutide before AF ablation can improve long-term rhythm outcomes and overall cardiovascular health. If successful, this strategy may offer a new approach to optimizing treatment and improving the results of catheter ablation for patients with AF and overweight or obesity

Read the detailed description

The WAIT trial evaluates whether metabolic optimization with once-weekly semaglutide prior to catheter ablation can improve rhythm outcomes in patients with atrial fibrillation and overweight/obesity. Excess adiposity and related cardiometabolic risk factors are strongly linked to atrial structural remodeling and higher rates of post-ablation arrhythmia recurrence. Although weight reduction is recommended in guidelines, sustained lifestyle-based weight loss is often difficult to achieve. Semaglutide provides an evidence-based pharmacologic strategy for clinically meaningful weight loss and risk-factor improvement, which may enhance the effectiveness of ablation.

This randomized, open-label study allocates participants 1:1 to semaglutide plus standard of care or standard of care alone for at least three months before undergoing their first AF ablation. All participants receive routine clinical management and continuous rhythm monitoring using an implantable loop recorder for 12 months post-ablation, with blinded adjudication of rhythm outcomes. The study integrates real-world clinical practice, using only routine clinical assessments, registry data, and ILR monitoring without introducing additional invasive procedures.

The trial is designed to determine whether targeted periablation metabolic therapy can increase arrhythmia-free survival, reduce AF burden, improve symptoms and quality of life, and favourably impact cardiovascular risk profiles. Results are expected to inform the role of GLP-1 receptor agonist therapy as part of a structured periablation optimization strategy for patients with AF and overweight or obesity.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Obesity & Overweight

Keywords

  • Semaglutide
  • Implantable Loop Recorder
  • Ablation
  • Pulmonary Vein Isolation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be included in the trial, subjects must meet all of the following criteria:

  1. Provision of written prior to participation.
  2. Age ≥18 years.
  3. Scheduled for first-time catheter ablation for atrial fibrillation using a pulmonary vein isolation (PVI) technique.
  4. (BMI) ≥30 kg/m² (obesity) OR

    BMI ≥27 kg/m² (overweight) with one or more of the following comorbidities:

    • prediabetes (defined as 39-47 mmol/mol or fasting glucose 5,6-6,9 mmol/L),
    • known diabetes type 2
    • known hypertension (prior diagnosis and/or treatment with antihypertensive medication)
    • new diagnosis of hypertension (according to ESC GL for hypertension: Systolic BP ≥140 mmHg and/or diastolic BP ≥ 90 mmHg based on two readings on two separate visits, OR Ambulatory BP monitoring (24h average) ≥ 130/80 mmHg)
    • dyslipidemia defined as either one of the following

      • Known diagnosis of hyperlipidemia or
      • Treatment with lipid lowering medication

    OR either of the following:

    • LDL > 3.0 mmol/l
    • Total cholesterol > 5 mmol/l
    • Triglycerides > 1.7 mmol/l
    • HDL (\< 1 mmol/l if male, \< 1.2 mmol/l if female) AND/OR

      • atherosclerotic cardiovascular disease (prior myocardial infarction (MI), stroke, or peripheral arterial disease with claudication and ankle-brachial index \<0.85, prior revascularization, or amputation)
      • obstructive sleep apnea.
  5. For women of : Inclusion after a highly sensitive negative pregnancy test and agreement to use highly effective during the study period (e.g., hormonal contraception, intrauterine device, or barrier method combined with spermicide).

Exclusion criteria

Exclusion Criteria:

  • Morbid obesity ( >40 kg/m²).
  • Current use of GLP-1 receptor agonist therapy or dual agonist therapy within 6 months before screening.
  • Current use of DPP-IV inhibitors.
  • Diabetes type 1
  • Known intolerance or to semaglutide.
  • History of pancreatitis or recurrent hypoglycemia.
  • Uncontrolled diabetic retinopathy
  • Severe renal failure (estimated [eGFR] \<15 mL/min/1.73 m² or in dialysis)
  • Severe hepatic failure (decompensated liver disease class C)
  • Severe cardiac failure ( class IV)
  • \<12 months.
  • Inability to self-administer the medicinal product.
  • Prior catheter ablation procedure for atrial fibrillation.
  • Pregnancy, breastfeeding, or planned pregnancy during or within two months after the study period.
  • Participation in another interventional clinical trial within the past 30 days.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Randomized to Semaglutide

    Participants randomized to the active arm receive once-weekly subcutaneous semaglutide (Wegovy®) initiated at 0.25 mg and uptitrated to a target dose of 2.4 mg as tolerated, according to the approved SmPC. Treatment begins ≥3 months before the planned first catheter ablation for atrial fibrillation. Participants receive structured lifestyle and weight-management advice in accordance with routine clinical practice.

    Drug: Semaglutide 2.4 mg · Behavioral: Standard medical treatment

  • Active comparator
    Standard of care

    Participants randomized to the standard-of-care arm receive routine clinical management for atrial fibrillation and weight-related comorbidities without GLP-1 receptor agonist therapy. Usual care may include lifestyle counselling, blood pressure and lipid management, treatment of dysglycaemia, and guideline-directed preparation for first-time catheter ablation. No trial-specific medicinal product is administered. Pa

    Behavioral: Standard medical treatment

Interventions

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The intervention consists of once-weekly subcutaneous semaglutide (Wegovy®), initiated at 0.25 mg and uptitrated to a target dose of 2.4 mg as tolerated, administered for at least three months prior to the participant's first planned atrial fibrillation ablation. Semaglutide is provided in pre-filled pens and used according to the approved SmPC for weight management. This intervention is uniquely characterized by pharmacological weight-loss therapy added on top of standard-of-care management, distinguishing it from the control arm, which receives identical clinical follow-up and lifestyle counselling but no GLP-1 receptor agonist. This allows evaluation of whether targeted metabolic therapy before ablation improves arrhythmia-related outcomes.

    Also known as: Standard of care

  • BehavioralStandard medical treatment

    Participants randomized to the standard-of-care arm receive routine clinical management for atrial fibrillation and weight-related comorbidities without GLP-1 receptor agonist therapy. Usual care may include lifestyle counselling, blood pressure and lipid management, treatment of dysglycaemia, and guideline-directed preparation for first-time catheter ablation. No trial-specific medicinal product is administered.

06

What researchers measure

Primary outcomes

  1. Arrhythmia-free survival at 12 months after catheter ablation, excluding the 3-month blanking period, with recurrence defined as any ILR-detected AF, atrial flutter, or atrial tachycardia ≥30 seconds.

    Arrhythmia-free survival at 12 months after catheter ablation, excluding the 3-month blanking period, with recurrence defined as any ILR-detected AF, atrial flutter, or atrial tachycardia ≥30 seconds.

    Time frame: 12 months post-ablation

Secondary outcomes

  1. Atrial fibrillation burden (%) measured by implantable loop recorder

    Atrial fibrillation burden measured using continuous monitoring from an implantable loop recorder (ILR). AF burden is defined as the percentage of total monitored time spent in atrial fibrillation during each predefined assessment window.

    Time frame: At ablation and at 12 months post-ablation.

  2. Per protocol analysis of the primary outcome

    Assessment of arrhythmia-free survival at 12 months post-ablation in participants who completed the study without major protocol deviations. Recurrence is defined identically to the primary ITT analysis (ILR-detected AF, atrial flutter, or atrial tachycardia ≥30 seconds after the blanking period). This analysis evaluates the treatment effect under optimal adherence.

    Time frame: 12 months post-ablation

  3. Time to first arrhythmia recurrence after the blanking period

    Time from the end of the 3-month post-ablation blanking period to the first ILR-detected episode of atrial fibrillation, atrial flutter, or atrial tachycardia lasting ≥30 seconds. This endpoint evaluates the durability of rhythm control beyond the blanking period.

    Time frame: From month 3 to month 12 post-ablation.

  4. Number of repeat ablations required to achieve sinus rhythm

    Total number of additional catheter ablation procedures performed per participant after the index ablation in order to restore or maintain sinus rhythm. This endpoint compares the need for redo ablations between the intervention and standard-of-care groups.

    Time frame: From index ablation to 12 months post-ablation.

  5. Freedom from symptomatic AF without redo ablation

    Proportion of participants who remain free from symptomatic atrial fibrillation, atrial flutter, or atrial tachycardia without requiring a repeat ablation procedure. Symptomatic episodes are defined by patient-reported symptoms corroborated by rhythm documentation. This endpoint evaluates clinically meaningful rhythm control without the need for additional invasive therapy.

    Time frame: From index ablation to 12 months post-ablation.

  6. Symptom burden using questionnaires at baseline, ablation, 12 months

    Assessment of atrial fibrillation-related symptom burden and functional impact using the AFEQT and AFSS validated questionnaires. Changes in symptom and quality-of-life scores will be compared between groups to evaluate improvement over time. Each questionnaire will be reported as a separate score.

    Time frame: At baseline, at the time of ablation, and at 12 months post-ablation

  7. Quality of life changes using RAND-36

    Assessment of changes in health-related quality of life using the RAND-36 questionnaire. A clinically meaningful change is defined as an improvement of approximately 3-5 points in any RAND-36 domain. This endpoint evaluates the impact of the intervention on physical, emotional, and functional well-being over time.

    Time frame: At baseline, at the time of ablation, and at 12 months post-ablation.

  8. Weight reduction and BMI category at follow-up

    Body weight (kg) and height (cm) will be measured using standard clinical equipment. Height and weight will be combined to calculate Body Mass Index (BMI) in kg/m², which will be the single reported value for this outcome. The endpoint is the proportion of participants who meet either of the following criteria: ≥10% reduction in baseline body weight (kg) BMI \<27 kg/m² (kg/m²) Only the derived values (weight change % and BMI) are reported for this outcome; height and weight are not reported as separate outcome measures

    Time frame: At the time of ablation and at 12 months post-ablation.

  9. Blood pressure reduction

    Change in systolic blood pressure in mmHg compared with baseline, and diastolic blood pressure in mmHg. The secondary outcome will focus on the proportion of participants achieving \>10% blood pressure reduction in either systolic or diastolic blood pressure. Systolic and diastolic blood pressure will be reported separately in mmHg. Measurements are performed using standardized clinical procedures to evaluate the intervention's impact on blood pressure control.

    Time frame: At baseline, at the time of ablation, and at 12 months post-ablation.

  10. Change in routine clinical blood biomarkers

    Changes in individual blood biomarkers measured as part of routine clinical care, including: Fasting glucose (mmol/L; standard chemistry assay) HbA1c (mmol/mol; HPLC/immunoassay) Serum creatinine (µmol/L; enzymatic/Jaffe assay) NT-proBNP (ng/L; immunoassay) Each biomarker will be analysed separately using its native unit of measure. Descriptive only. No study-specific blood sampling is performed.

    Time frame: At routine clinical assessments nearest to baseline, ablation, and 12 months post-ablation.

  11. Complications during and after the ablation procedure

    Incidence of procedure-related complications occurring during the catheter ablation or within the post-procedural follow-up period. Events may include vascular complications, pericardial effusion, tamponade, stroke/TIA, transient arrhythmias, anesthesia-related events, or other clinically relevant adverse outcomes, as documented in medical records. This endpoint compares procedural safety between study groups.

    Time frame: During the ablation procedure and through 12 months post ablation.

  12. Left ventricular ejection fraction (LV-EF) pre- and post-ablation

    Assessment of changes in left ventricular ejection fraction from before to after the ablation procedure, based solely on echocardiograms performed as part of routine clinical care. No study-specific imaging is required; data will be included only for participants who undergo a post-ablation echocardiogram in standard practice. This endpoint evaluates whether the intervention influences cardiac function over time.

    Time frame: At routine clinical echocardiography closest to baseline and the post-ablation assessment (up to 12 months).

  13. Prevalence of diabetes, renal failure, and heart failure

    Assessment of the proportion of participants with diabetes, renal failure, or heart failure using information from routine clinical care, medical records, and linked registry data. No study-specific testing is performed. This endpoint describes baseline comorbidity burden and identifies new or worsening diagnoses captured through standard care or registries.

    Time frame: At baseline and at 12 months post-ablation (via clinical records and registry data).

  14. Cardiovascular hospitalization

    Incidence of hospitalizations due to cardiovascular causes, identified through routine clinical records and national or regional registry data. Events may include admissions for arrhythmias, heart failure, acute coronary syndromes, or other cardiovascular conditions. No study-specific assessments are required.

    Time frame: From index ablation to 12 months post-ablation.

  15. All-cause hospitalization

    Incidence of hospital admissions for any cause, identified through routine clinical records and national or regional registry data. This endpoint evaluates the broader healthcare impact of the intervention beyond cardiovascular events. No study-specific assessments are required.

    Time frame: From index ablation to 12 months post-ablation.

  16. Change in antiarrhythmic drug use

    Assessment of initiation, discontinuation, or dose changes in antiarrhythmic medications (e.g., class I or III agents, beta-blockers) based on routine clinical records. This endpoint evaluates differences in pharmacologic rhythm control requirements between groups.

    Time frame: From baseline to 12 months post-ablation.

  17. Ablation procedure duration

    Total duration of the catheter ablation procedure, extracted from routine procedural reports. This endpoint evaluates whether pre-ablation metabolic optimization influences procedural complexity.

    Time frame: During the index ablation procedure.

  18. Fluoroscopy time and radiation dose

    Total fluoroscopy exposure time and radiation dose recorded during the index ablation procedure, as documented in routine procedural logs. This endpoint assesses potential differences in radiation exposure related to patient characteristics or weight loss. Fluoroscopy time (minutes) and radiation dose (mGy or mGy·cm²) will be reported as separate values.

    Time frame: During the index ablation procedure.

  19. Healthcare utilization

    Assessment of overall healthcare use, including outpatient cardiology visits, emergency department visits, and telephone/remote consultations. Data will be obtained from routine clinical records and linked regional or national healthcare registries. This endpoint evaluates whether the intervention affects healthcare demand and resource use. No study-specific visits or assessments are required.

    Time frame: From randomization to 12 months post-ablation.

Other outcomes

  1. Artificial-intelligence based prediction of arrhythmia recurrence from 12-lead ECG

    Exploratory assessment of whether artificial intelligence (AI) analysis of standard 12-lead ECGs can predict arrhythmia recurrence after ablation. ECGs obtained through routine clinical care will be analysed using validated AI algorithms to evaluate associations between ECG-derived features and later recurrence captured by ILR monitoring. No study-specific ECGs are required.

    Time frame: ECGs recorded as part of routine care at baseline, at ablation, and during follow-up up to 12 months post-ablation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to GDPR and national data protection regulations, the use of identifiable clinical and registry-linked data, and the absence of a fully anonymised IPD-sharing infrastructure. Data will only be accessible to authorised study personnel and regulatory bodies as required. Summary results will be published in accordance with scientific and ethical standards.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 33 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2025
First posted
Dec 10, 2025
StartActual
Mar 23, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07275697
Lead sponsor
Emma Svennberg
Responsible party
Emma Svennberg (Associate professor, Consultant, Karolinska University Hospital) — Sponsor-investigator
First posted
Dec 10, 2025
Start date
Mar 23, 2026
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Emma Svennberg, MD PhD
Contact
emma.svennberg@regionstockholm.se
+46739584822
Ewa Molaei, RN
Contact
ewa.molaei@regionstockholm.se
+46812381692
Emma Svennberg, MD PhD
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion